Literature DB >> 810533

Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia.

R J Weinstein, L S Young, W L Hewitt.   

Abstract

Infections with Pseudomonas aeruginosa and Serratia marcescens are often difficult to treat because of the narrow therapeutic ratio of available antimicrobials. Synergistic inhibitory and bactericidal activity for gentamicin and carbenicillin against P. aeruginosa has been documented in vitro. The purpose of this study was to compare 4 methods of determining in vitro synergism between several aminoglycosides and penicillins. The agar dilution method using an inoculum replicator was employed, and a drug combination showing inhibition equal to or less than one-fourth of the individual minimal inhibitory concentrations was termed synergistic. Combinations using amikacin and BL-P1654 showed synergism against a greater per cent of strains of P. aeruginosa and S. marcescens than combinations using gentamicin or carbenicillin. Additionally, the "checkerboard" broth dilution method using both minimal inhibitory concentration and minimal bactericidal concentration as endpoints and killing curves according to the methods of Jawetz was studied. Comparison of the results of these 4 methods showed excellent correlation, verifying the consistency of the 4 techniques for determining in vitro synergism.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 810533

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  20 in total

1.  Polymyxin B and rifampin: new regimen for multiresistant Serratia marcescens infections.

Authors:  R C Ostenson; B T Fields; C M Nolan
Journal:  Antimicrob Agents Chemother       Date:  1977-12       Impact factor: 5.191

2.  Synergistic action of erythromycin and cefamandole against Bacteroides fragilis subsp. fragilis.

Authors:  R S Griffith; G L Brier; J D Wolny
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

3.  In vitro synergism between carbenicillin and aminoglycosidic aminocyclitols against Acinetobacter calcoaceticus var. anitratus.

Authors:  R H Glew; R C Moellering; K R Buettner
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

4.  Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test.

Authors:  R L White; D S Burgess; M Manduru; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

5.  In vitro susceptibility of Haemophilus influenzae to sulfamethoxazole-trimethoprim and cefaclor, cephalexin, and cephradine.

Authors:  R Sinai; S Hammerberg; M I Marks; C H Pai
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

6.  The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions.

Authors:  R C Li; J J Schentag; D E Nix
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

7.  Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method.

Authors:  H O Hallander; K Dornbusch; L Gezelius; K Jacobson; I Karlsson
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

8.  In vitro activity of gentamicin, amikacin and netilmicin alone and in combination with carbenicillin against Serratia marcescens.

Authors:  S M Pogwizd; S A Lerner
Journal:  Antimicrob Agents Chemother       Date:  1976-12       Impact factor: 5.191

9.  In vitro synergistic effect of netilmicin, a new aminoglycoside antibiotic.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

10.  In vitro antimicrobial activity of aztreonam alone and in combination against bacterial isolates from pediatric patients.

Authors:  H R Stutman; D F Welch; R K Scribner; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.